TY - JOUR
T1 - Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer
AU - Takabatake, Daisuke
AU - Kajiwara, Yukiko
AU - Ohtani, Shoichiro
AU - Suzuki, Yoko
AU - Yamamoto, Mari
AU - Kubo, Shinichiro
AU - Ikeda, Masahiko
AU - Takahashi, Mina
AU - Hara, Fumikata
AU - Aogi, Kenjiro
AU - Ohsumi, Shozo
AU - Ogasawara, Yutaka
AU - Nishiyama, Yoshitaka
AU - Hikino, Hajime
AU - Matsuoka, Kinya
AU - Shien, Tadahiko
AU - Taira, Naruto
AU - Doihara, Hiroyoshi
N1 - Funding Information:
Acknowledgments. We thank the patients who participated in the Setouch Breast Project (SBP09) clinical trial. This study was supported by the Setouch Breast Comprehensive Support Project, which is a non-profit organization in Okayama, Japan. We would like to thank KN international for English language editing.
Publisher Copyright:
© 2021, Acta Medica Okayama. All Rights Reserved.
PY - 2021
Y1 - 2021
N2 - Perioperative dose-dense chemotherapy (DDCT) with pegfilgrastim (Peg) prophylaxis is a standard treatment for high-risk breast cancer. We explored the optimal timing of administration of 3.6 mg Peg, the dose approved in Japan. In the phase II feasibility study of DDCT (adriamycin+cyclophosphamide or epirubicin+cyclophosphamide followed by paclitaxel) for breast cancer, we investigated the feasibility, safety, neutrophil transition, and optimal timing of Peg treatment by administering Peg at days 2, 3, and 4 post-chemotherapy (P2, P3, and P4 groups, respectively). Among the 52 women enrolled, 13 were aged > 60 years. The anthracycline sequence was administered to P2 (n=33), P3 (n=5), and P4 (n=14) patients, and the taxane sequence to P2 (n=38) and P3 (n=6) patients. Both sequences showed no interaction between Peg administration timing and treatment discontinuation, treatment delay, or dose reduction. However, the relative dose intensity (RDI) was significantly different among the groups. The neutrophil count transition differed significantly among the groups receiving the anthracycline sequence. However, the neutrophil count remained in the appropriate range for both sequences in the P2 group. The timing of Peg administration did not substantially affect the feasibility or safety of DDCT. Postoperative day 2 might be the optimal timing for DDCT.
AB - Perioperative dose-dense chemotherapy (DDCT) with pegfilgrastim (Peg) prophylaxis is a standard treatment for high-risk breast cancer. We explored the optimal timing of administration of 3.6 mg Peg, the dose approved in Japan. In the phase II feasibility study of DDCT (adriamycin+cyclophosphamide or epirubicin+cyclophosphamide followed by paclitaxel) for breast cancer, we investigated the feasibility, safety, neutrophil transition, and optimal timing of Peg treatment by administering Peg at days 2, 3, and 4 post-chemotherapy (P2, P3, and P4 groups, respectively). Among the 52 women enrolled, 13 were aged > 60 years. The anthracycline sequence was administered to P2 (n=33), P3 (n=5), and P4 (n=14) patients, and the taxane sequence to P2 (n=38) and P3 (n=6) patients. Both sequences showed no interaction between Peg administration timing and treatment discontinuation, treatment delay, or dose reduction. However, the relative dose intensity (RDI) was significantly different among the groups. The neutrophil count transition differed significantly among the groups receiving the anthracycline sequence. However, the neutrophil count remained in the appropriate range for both sequences in the P2 group. The timing of Peg administration did not substantially affect the feasibility or safety of DDCT. Postoperative day 2 might be the optimal timing for DDCT.
KW - breast cancer
KW - dose-dense chemotherapy
KW - pegfilgrastim
UR - http://www.scopus.com/inward/record.url?scp=85109423865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109423865&partnerID=8YFLogxK
M3 - Article
C2 - 34176940
AN - SCOPUS:85109423865
VL - 75
SP - 357
EP - 362
JO - Acta Medica Okayama
JF - Acta Medica Okayama
SN - 0386-300X
IS - 3
ER -